'/main.js?v=3';s.defer=true;document.head.appendChild(s);})();
Evidence-Informed Nutrition Support

High LDL / ApoB & Cardiovascular Risk

Nutrition strategies associated with improved lipid markers and reduced atherogenic particle burden in human studies.

Framing: ApoB and LDL-P are stronger predictors of cardiovascular events than LDL-C. Every recommendation links to human trial evidence. This complements, not replaces, statin therapy when indicated.

1 — What the evidence supports

Strong — Multiple RCTs
  • Dietary fiber ≥25–35g/day reduces LDL-C ~5–10% (Reynolds 2019, Lancet)
  • Plant sterols/stanols 2g/day reduce LDL-C 8–10% — multiple RCTs, FDA-qualified claim
  • EPA+DHA Omega-3 ≥2g/day reduces triglycerides 15–30% (REDUCE-IT, STRENGTH)
  • DASH diet reduces LDL-C and blood pressure (Appel 1997, NEJM)
  • Replacing saturated with poly/monounsaturated fat reduces ApoB
Moderate — Consistent signal
  • Walnuts 1 oz/day reduce LDL-C (WAHA trial)
  • Green tea catechins: modest LDL-C reduction (~5mg/dL)
  • Oat beta-glucan 3g/day — FDA claim for LDL reduction

2 — Weak or overhyped

  • Coconut oil: raises LDL-C reliably — no CV benefit evidence
  • Niacin on top of statins: AIM-HIGH and HPS2-THRIVE showed no additional CV benefit
  • Antioxidant megadoses: Vitamin E and beta-carotene showed no CV benefit in RCTs
  • Egg restriction in healthy adults: evidence is weaker than once thought — genetics (APOE4) matter

3 — Foods to emphasize

  • Legumes daily
  • Ground flaxseed 2 tbsp/day
  • Oats and barley — beta-glucan 3g/day
  • Fatty fish 2–3×/week
  • Nuts — almonds, walnuts, pistachios
  • Olive oil replacing saturated fats
  • Avocado
  • Plant sterol-fortified foods

4 — Foods to reduce

  • Full-fat dairy in excess
  • Processed and red meat
  • Trans fats (still in some fried foods)
  • Coconut oil and palm oil
  • Refined carbohydrates (raises triglycerides)
  • Alcohol in excess

5 — Key labs to track

Primary
  • ApoB (primary target)
  • LDL-C and LDL-P
  • Triglycerides
  • Lp(a) — genetic, unaffected by diet
Secondary
  • HDL-C (context only)
  • hsCRP (inflammation)
  • Fasting glucose
  • Lipoprotein fractionation
Tracking
  • No reliable wearable lipid tracking
  • CGM if metabolic risk co-exists
  • BP monitoring
  • Weight trend

6 — Supplement considerations

Evidence-graded. Click any to see the full EBL evidence card.
EPA/DHA Omega-3
REDUCE-IT: 25% MACE reduction at 4g/d icosapent ethyl
Tier 1 · Grade A
Berberine
LDL −21% in head-to-head RCT vs metformin — lipid and glucose effects
Tier 2 · Grade B
CoQ10
Cardiac support in heart failure; not a primary lipid agent
Tier 2 · Grade B

⚠ Medication & Nutrient Cautions

  • Red yeast rice + statins: additive rhabdomyolysis risk — physician oversight required
  • Omega-3 ≥3g/day + anticoagulants: increased bleeding risk — coordinate with prescriber
  • Niacin + statins: no additional CV benefit; elevated muscle toxicity risk

Full contraindications tool → · Drug-nutrient depletion checker →

8 — When to consult your physician

  • LDL-C ≥190 mg/dL (guideline statin threshold)
  • ApoB ≥130 mg/dL with any CV risk factor
  • Lp(a) ≥75 nmol/L — not diet-responsive
  • Known atherosclerosis (prior MI, stroke, CAD)
  • Before starting red yeast rice — carries same risks as lovastatin
  • Family history of early cardiovascular disease
Related conditions & tools
Insulin Resistance →Hypertension →CV supplements →Contraindications →